By Trend News Line 2024-03-28 12:32:52.
Patent Approval for ReShape Lifesciences
In a recent development, ReShape Lifesciences® has received a Notice of Allowance from the U.S. Patent and Trademark Office for their patent application related to an Intragastric Device. The company, known for its innovative weight loss and metabolic health solutions, is set to strengthen its intellectual property portfolio with this new patent approval.
You may also like to watch : Who Is Kamala Harris? Biography - Parents - Husband - Sister - Career - Indian - Jamaican Heritage
Significance of the Patent
The patent, once issued, will cover claims for an intragastric balloon system, providing protection for the technology until at least January 2031. This development marks a significant accomplishment for ReShape Lifesciences, ensuring comprehensive protection for their innovative solutions.
Statement from CEO
Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences, expressed his satisfaction with the patent approval. He highlighted the company’s commitment to building a defensive ‘moat’ around their product portfolio and innovation efforts. With over 50 patents secured for the intragastric balloon system, ReShape Lifesciences continues to lead in the field of weight loss and metabolic health solutions.
About ReShape Lifesciences®
ReShape Lifesciences® is at the forefront of providing integrated products and services for managing and treating obesity and metabolic diseases. Their FDA-approved Lap-Band® System offers a minimally invasive, long-term solution for obesity, while the Obalon® balloon technology provides a non-surgical, swallowable option for weight loss. The company’s commitment to innovation and commercialization is evident in their extensive patent portfolio.
Forward-Looking Statements
While celebrating the patent approval, ReShape Lifesciences acknowledges the risks and uncertainties that come with such developments. The company remains focused on future intellectual property protection measures and is prepared to address any challenges that may arise. By staying proactive and innovative, they aim to maintain their position as a leader in the industry.
You may also like to watch: Is US-NATO Prepared For A Potential Nuclear War With Russia - China And North Korea?
Contact Information
For more information about ReShape Lifesciences and their products, visit their official website. Investors and media personnel can reach out to the company’s designated contacts for further inquiries:
- Investor Contact: Paul F. Hickey, President and Chief Executive Officer – 949-276-7223, ir@ReShapeLifesci.com
- Investor Relations Contact: Rx Communications Group, Michael Miller – 917-633-6086, mmiller@rxir.com
This breaking news is brought to you by GlobeNewswire, Inc. Stay tuned for more updates on ReShape Lifesciences® and their groundbreaking advancements in weight loss and metabolic health solutions.
.
long-tailed keyword: ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to an
long-tailed keyword: ReShape Lifesciences Patent Notice of Allowance U.S..
